Plague Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Plague
Plague Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Plague Infection pipeline products.
DISEASE OVERVIEW
Plague infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Plague Infection pipeline guide presents complete overview of drugs currently being developed for Plague Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Plague Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Plague Infection pipeline candidates is included.
Major companies participating in therapeutic development of Plague Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Plague Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Plague Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Plague Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF PLAGUE INFECTION PIPELINE REPORT INCLUDES
DISEASE OVERVIEW
Plague infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.
Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.
Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.
REPORT DESCRIPTION
The Plague Infection pipeline guide presents complete overview of drugs currently being developed for Plague Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).
Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Plague Infection pipeline candidate.
Research and Development progress along with latest news related to each of the Plague Infection pipeline candidates is included.
Major companies participating in therapeutic development of Plague Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.
Amid strong interest for cure of Plague Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Plague Infection clinical and pre-clinical products.
The report assists in identifying potential upcoming companies and drugs in Plague Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF PLAGUE INFECTION PIPELINE REPORT INCLUDES
- Panorama of Plague Infection pipeline markets including statistics on therapeutic drugs and companies involved
- Plague Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
- Plague Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
- Overview of companies participating in Plague Infection pipeline with short introduction to their businesses and pipeline projects
- For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
- Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Plague Infection pipeline therapeutics
- Get clear understanding of the entire Plague Infection pipeline, with details on active projects
- Get in detail information of each product with updated information on each project along with key milestones
- Know the list of companies participating in global Plague Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
I. KEY FINDINGS
1. Companies Investing in Plague Infection Pipeline include
Number of Companies with Plague Infection projects in pre-clinical Development
Number of Companies with Plague Infection projects in Clinical Development
Plague Infection Pipeline Companies based in Americas
Plague Infection Pipeline Companies based in Europe
Plague Infection Pipeline Companies based in Asia Pacific
Plague Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
Plague Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
Plague Infection Pipeline Agents in Clinical Development stage
Plague Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Plague Infection Pipeline agents
II. INSIGHTS INTO PLAGUE INFECTION PIPELINE
1. Disease Overview
Introduction to Plague Infection
Symptoms and Causes of Plague Infection
Treatment or Prevention Options for Plague Infection
Other Details
2. Phase wise Pipeline Compounds
Plague Infection Pipeline Pre- Clinical/Discovery stage Drugs
Plague Infection Pipeline Phase 1 stage Drugs
Plague Infection Pipeline Phase 2 stage Drugs
Plague Infection Pipeline Phase 3 stage Drugs
Plague Infection Pipeline Pre-Registration stage Drugs
3. Company wise Plague Infection Pipeline Compounds
4. Plague Infection Pipeline by Mechanism of Action
III. PLAGUE INFECTION PIPELINE COMPOUND DETAILS
plazomicin sulfate
Ciprofloxacin
L-97-1
Immune stimulating adjuvant system
GrePla
plague-anthrax combination vaccine
trivalent adenoviral vaccine
Omadacycline
Plague vaccine
Yersinia pestis vaccine
TP-271
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. PLAGUE INFECTION PIPELINE COMPANY BRIEFS
Achaogen Inc
Aradigm Corp
Endacea Inc
FasCure Therapeutics LLC
Greffex Inc
iBio Inc
Norwell Inc
Paratek Pharmaceuticals
Prokarium Ltd
Syntiron LLC
Tetraphase Pharmaceuticals Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL PLAGUE INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
1. Companies Investing in Plague Infection Pipeline include
Number of Companies with Plague Infection projects in pre-clinical Development
Number of Companies with Plague Infection projects in Clinical Development
Plague Infection Pipeline Companies based in Americas
Plague Infection Pipeline Companies based in Europe
Plague Infection Pipeline Companies based in Asia Pacific
Plague Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
Plague Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
Plague Infection Pipeline Agents in Clinical Development stage
Plague Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Plague Infection Pipeline agents
II. INSIGHTS INTO PLAGUE INFECTION PIPELINE
1. Disease Overview
Introduction to Plague Infection
Symptoms and Causes of Plague Infection
Treatment or Prevention Options for Plague Infection
Other Details
2. Phase wise Pipeline Compounds
Plague Infection Pipeline Pre- Clinical/Discovery stage Drugs
Plague Infection Pipeline Phase 1 stage Drugs
Plague Infection Pipeline Phase 2 stage Drugs
Plague Infection Pipeline Phase 3 stage Drugs
Plague Infection Pipeline Pre-Registration stage Drugs
3. Company wise Plague Infection Pipeline Compounds
4. Plague Infection Pipeline by Mechanism of Action
III. PLAGUE INFECTION PIPELINE COMPOUND DETAILS
plazomicin sulfate
Ciprofloxacin
L-97-1
Immune stimulating adjuvant system
GrePla
plague-anthrax combination vaccine
trivalent adenoviral vaccine
Omadacycline
Plague vaccine
Yersinia pestis vaccine
TP-271
Drug Details
1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/License Partner
Orphan Drug/Fast Track/Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details
IV. PLAGUE INFECTION PIPELINE COMPANY BRIEFS
Achaogen Inc
Aradigm Corp
Endacea Inc
FasCure Therapeutics LLC
Greffex Inc
iBio Inc
Norwell Inc
Paratek Pharmaceuticals
Prokarium Ltd
Syntiron LLC
Tetraphase Pharmaceuticals Inc
V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL PLAGUE INFECTION PIPELINE MARKET
VI. APPENDIX
1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability
